NSE ScannerOpen the scanner

Pharmaceuticals · Pharmaceuticals: Major · NSE: NECLIFE · data 2026-10-30

Nectar Lifesciences Ltd.

₹10.2-1.26% on 30 OctHealth: Weak 0/10
Feb 2026Low ₹9.3 · High ₹14.36-24.2%

In plain words

Price: 54.5% below its 52-week high of ₹22.4.

Delivery: 76.9% of traded shares were kept for delivery over the last 10 sessions, against 74.8% over the last 60.

A description of the data, not a recommendation.

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price
₹10.2
Market cap
₹200 cr
P/E
—
P/B
—
ROE
-7.5%
ROCE
-0.9%
Debt / equity
0
Dividend yield
0.00%
1-year return
-38.3%
52-week high
₹22.4
52-week low
₹9.3
Operating margin
-1171.9%

Growth

Revenue (last 12 months)₹7 cr
Net profit (last 12 months)₹-245 cr
Sales growth, 3 years (yearly)-90.6%
Profit growth, 3 years (yearly)—

Smart-money activity

11/100 · Weak over the last ~60 sessions, data 2026-10-30

A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.

Common questions

Is Nectar Lifesciences Ltd. debt-free?

Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.

What is the 52-week high and low of Nectar Lifesciences Ltd.?

The 52-week high is ₹22.4 and the 52-week low is ₹9.3.

Similar companies

Ambalal Sarabhai Enterprises Limited (AMBALALSA) · Accretion Pharmaceuticals Ltd. (ACCPL) · Brooks Laboratories Limited (BROOKS) · Medico Remedies Ltd. (MEDICO) · Curis Lifesciences Limited (CURIS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open NECLIFE in NSE Scanner →
Share on WhatsAppShare on Telegram